トーカイ has revised upward its full-year earnings and dividend forecasts for the fiscal year ending March 2027. Both revenue and profit are expected to reach record levels, with the year-end dividend increasing by ¥9 to ¥49 and the annual dividend totaling ¥89. QLC Produce will be included in the consolidated results from the third quarter onward, and achievement of the final-year target is expected to be brought forward.
トーカイ has revised upward its full-year earnings forecast for the fiscal year ending March 2027, raising revenue from the previous forecast of ¥165,400 million to ¥167,980 million (up 1.6%), operating profit from ¥8,985 million to ¥10,286 million (up 14.5%), ordinary profit from ¥9,437 million to ¥10,716 million (up 13.5%), and net income attributable to owners of the parent from ¥6,117 million to ¥6,866 million (up 12.2%). The metrics for which a decline in profit had been forecast previously are now expected to increase, with all of them projected to reach record levels.
In the interim period, prescription prices in the dispensing pharmacy business exceeded plan for both drug and technical fees, while the continued effect of rental equipment operations in the senior-care business led to a marked improvement in profit. The dispensing pharmacy business is expected to remain strong from the third quarter onward, and QLC Produce, which has been brought into the group, will be included in the consolidated results from the third quarter.
Following this revision, the company is expected to achieve the ¥9.5 billion consolidated operating profit target for the fiscal year ending March 2028, the final year of its medium-term management plan, one year ahead of schedule. On dividends, the year-end dividend will be raised from ¥40 to ¥49, bringing the annual dividend to ¥89.
The company also indicated a policy of raising its target payout ratio to 40% in May 2026.